ASCO to shine light on CAR-T developments
May 19, 2017Kite, Juno, and BlueBird will give updates on T-cell therapies.
X
ASCO to shine light on CAR-T developments
https://pharmaphorum.com/news/asco-shine-light-car-t-developments/
CAR T
Kite shares sink after death in CAR-T trial
May 9, 2017Investors spooked after cerebral oedema death.
Kite keeps pressure on Novartis with CAR-T filing
April 3, 2017Kite completes filing a day after rival Novartis.
Novartis edges ahead in CAR-T race
March 30, 2017Servier and Pfizer begin trials for off-the-shelf T-cell cancer therapy
March 10, 2017Companies hope to challenge traiblazers Novartis and Kite.
Kite and Fosun appoint leader for CAR-T debut in China
March 6, 2017But rival Juno finally gives up on lead therapy.
Interview: Vas Narasimhan on Novartis’ goal to lead in CAR-T therapies
March 2, 2017Novartis’ head of drug development talks about its stake in CAR-T immunotherapy. These cell therapies are set to transform treatment of blood cancers – but questions about safety, manufacturing and cost versus clinical value remain
Orphan drugs will fuel pharma’s future – and a pricing pushback too
March 1, 2017Evaluate predicts sales could approach $8bn if approved.
Kite’s CAR-T therapy most valuable pipeline orphan drug
March 1, 2017Drug tops list compiled by Evaluate Pharma
